DaVita Inc. $DVA Shares Acquired by Arrowstreet Capital Limited Partnership

Arrowstreet Capital Limited Partnership boosted its holdings in DaVita Inc. (NYSE:DVA) by 114.9% during the 4th quarter, Holdings Channel reports. The fund owned 1,190,000 shares of the company’s stock after acquiring an additional 636,191 shares during the quarter. Arrowstreet Capital Limited Partnership’s holdings in DaVita were worth $135,196,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently added to or reduced their stakes in the business. Todd Asset Management LLC acquired a new position in DaVita during the 3rd quarter valued at about $21,842,000. Doma Perpetual Capital Management LLC lifted its stake in shares of DaVita by 23.3% in the 3rd quarter. Doma Perpetual Capital Management LLC now owns 355,574 shares of the company’s stock worth $47,245,000 after acquiring an additional 67,214 shares during the period. Intech Investment Management LLC boosted its holdings in shares of DaVita by 122.4% in the third quarter. Intech Investment Management LLC now owns 27,441 shares of the company’s stock valued at $3,646,000 after acquiring an additional 15,104 shares in the last quarter. Nordea Investment Management AB increased its stake in shares of DaVita by 18.0% during the fourth quarter. Nordea Investment Management AB now owns 338,192 shares of the company’s stock valued at $38,321,000 after acquiring an additional 51,607 shares during the period. Finally, Munich Reinsurance Co Stock Corp in Munich bought a new stake in DaVita during the third quarter worth approximately $5,419,000. Institutional investors own 90.12% of the company’s stock.

Insider Transactions at DaVita

In other DaVita news, CFO Joel Ackerman sold 51,471 shares of the business’s stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $192.10, for a total transaction of $9,887,579.10. Following the sale, the chief financial officer owned 132,434 shares in the company, valued at approximately $25,440,571.40. The trade was a 27.99% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 1.50% of the company’s stock.

DaVita Stock Performance

Shares of NYSE:DVA opened at $209.29 on Tuesday. The company has a market capitalization of $13.44 billion, a PE ratio of 19.41, a price-to-earnings-growth ratio of 0.68 and a beta of 0.91. The stock has a fifty day moving average of $177.40 and a 200-day moving average of $146.89. DaVita Inc. has a one year low of $101.00 and a one year high of $211.80.

DaVita (NYSE:DVA) last announced its earnings results on Tuesday, May 5th. The company reported $2.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.33 by $0.54. DaVita had a negative return on equity of 270.37% and a net margin of 5.65%.The company had revenue of $3.42 billion for the quarter, compared to analyst estimates of $3.36 billion. During the same period in the previous year, the firm earned $2.00 earnings per share. DaVita’s revenue for the quarter was up 6.0% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, research analysts forecast that DaVita Inc. will post 15.07 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. Barclays increased their price target on DaVita from $158.00 to $194.00 and gave the company an “equal weight” rating in a research note on Thursday, May 7th. Truist Financial upped their price objective on DaVita from $158.00 to $205.00 and gave the company a “hold” rating in a report on Friday, May 8th. Zacks Research raised DaVita from a “hold” rating to a “strong-buy” rating in a research note on Thursday, May 7th. Wall Street Zen raised DaVita from a “hold” rating to a “buy” rating in a report on Saturday, February 21st. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of DaVita from a “hold” rating to a “buy” rating and boosted their price target for the stock from $126.00 to $220.00 in a research report on Wednesday, May 6th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, DaVita has a consensus rating of “Hold” and a consensus price target of $199.17.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.